Analysed GENPREX INC (GNPX:NASDAQ) News Sources
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
22-04-2026
yahoo.com
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy
21-04-2026
yahoo.com
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
20-04-2026
yahoo.com
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
18-03-2026
yahoo.com
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
23-02-2026
yahoo.com
Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
10-02-2026
yahoo.com
Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies
06-01-2026
yahoo.com
What is the current price of GENPREX INC (GNPX:NASDAQ)?
The current price of GENPREX INC (GNPX:NASDAQ) is $1.02.
GENPREX INC (GNPX:NASDAQ) absolute price change since previous trading day?
The absolute price change of GENPREX INC (GNPX:NASDAQ) since the previous trading day is $-0.07.
GENPREX INC (GNPX:NASDAQ) percentage price change since previous trading day?
The percentage price change of GENPREX INC (GNPX:NASDAQ) since the previous trading day is -6.422%.
What is the most recent average sentiment score for GENPREX INC (GNPX:NASDAQ)?
The most recent average sentiment score for GENPREX INC (GNPX:NASDAQ) is 86 out of 100.
What is the most recent average sentiment for GENPREX INC (GNPX:NASDAQ)?
The most recent sentiment for GENPREX INC (GNPX:NASDAQ) is .
SEC-8K** Filing Available For GENPREX INC (GNPX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.